Strong opioid prescription in cancer patients in their final year of life: A population-based analysis using a Taiwanese health insurance database

Yu Lin Lin, Ruey Kuen Hsieh, Chao Hsiun Tang

Research output: Contribution to journalArticle

Abstract

Aim: Pain assessment and management have been important criteria in hospital accreditation in Taiwan since 2007. We used a Taiwanese health insurance database to determine factors influencing patterns of strong opioid use in cancer patients in their final 12 months of life. Methods: Data from patients with cancer in Taiwan outpatient clinics with cancer-related deaths between 2008 and 2011 were included in the analysis. Strong opioid prescription data from the last 12 months of each patient's life, as well as patient, physician, and hospital characteristics, were collected from the National Health Insurance Research Database. Results: Among 162 679 patients, more were male (63.6%) than female (36.4%) and almost half (49.3%) were ≥70 years old. Most (44.9%) patients had gastrointestinal cancer. More than one-third (35.4%) of patients were prescribed strong opioids during the 12 months before death, and more than half (53.2%) of those prescribed opioids received them in the 3 months before death. Median duration of strong opioid use was 81 days before death. Patients with head/neck cancer (52.8%) or who were treated in hematology and oncology departments (45.8%) were most likely, and patients with gastrointestinal cancer (hazard ratio = 0.65; 95% confidence interval, 0.64-0.67) or treated in gastroenterology departments (hazard ratio = 0.88; 95% confidence interval, 0.84-0.93) were least likely to be prescribed strong opioids. Conclusion: Strong opioid prescriptions varied among patients with different cancer diagnoses and physicians. Information from this study can guide efforts to improve patient and physician education about cancer pain management.

Original languageEnglish
JournalAsia-Pacific Journal of Clinical Oncology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Health Insurance
Opioid Analgesics
Prescriptions
Databases
Population
Neoplasms
Gastrointestinal Neoplasms
Pain Management
Physicians
Taiwan
Confidence Intervals
Accreditation
National Health Programs
Hematology
Gastroenterology
Patient Education
Pain Measurement
Head and Neck Neoplasms
Ambulatory Care Facilities

Keywords

  • Cancer
  • Opioid
  • Pain
  • Prescriptions
  • Taiwan

ASJC Scopus subject areas

  • Oncology

Cite this

@article{efb661bc942f4528851586387830fd6c,
title = "Strong opioid prescription in cancer patients in their final year of life: A population-based analysis using a Taiwanese health insurance database",
abstract = "Aim: Pain assessment and management have been important criteria in hospital accreditation in Taiwan since 2007. We used a Taiwanese health insurance database to determine factors influencing patterns of strong opioid use in cancer patients in their final 12 months of life. Methods: Data from patients with cancer in Taiwan outpatient clinics with cancer-related deaths between 2008 and 2011 were included in the analysis. Strong opioid prescription data from the last 12 months of each patient's life, as well as patient, physician, and hospital characteristics, were collected from the National Health Insurance Research Database. Results: Among 162 679 patients, more were male (63.6{\%}) than female (36.4{\%}) and almost half (49.3{\%}) were ≥70 years old. Most (44.9{\%}) patients had gastrointestinal cancer. More than one-third (35.4{\%}) of patients were prescribed strong opioids during the 12 months before death, and more than half (53.2{\%}) of those prescribed opioids received them in the 3 months before death. Median duration of strong opioid use was 81 days before death. Patients with head/neck cancer (52.8{\%}) or who were treated in hematology and oncology departments (45.8{\%}) were most likely, and patients with gastrointestinal cancer (hazard ratio = 0.65; 95{\%} confidence interval, 0.64-0.67) or treated in gastroenterology departments (hazard ratio = 0.88; 95{\%} confidence interval, 0.84-0.93) were least likely to be prescribed strong opioids. Conclusion: Strong opioid prescriptions varied among patients with different cancer diagnoses and physicians. Information from this study can guide efforts to improve patient and physician education about cancer pain management.",
keywords = "Cancer, Opioid, Pain, Prescriptions, Taiwan",
author = "Lin, {Yu Lin} and Hsieh, {Ruey Kuen} and Tang, {Chao Hsiun}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/ajco.12865",
language = "English",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Strong opioid prescription in cancer patients in their final year of life

T2 - A population-based analysis using a Taiwanese health insurance database

AU - Lin, Yu Lin

AU - Hsieh, Ruey Kuen

AU - Tang, Chao Hsiun

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aim: Pain assessment and management have been important criteria in hospital accreditation in Taiwan since 2007. We used a Taiwanese health insurance database to determine factors influencing patterns of strong opioid use in cancer patients in their final 12 months of life. Methods: Data from patients with cancer in Taiwan outpatient clinics with cancer-related deaths between 2008 and 2011 were included in the analysis. Strong opioid prescription data from the last 12 months of each patient's life, as well as patient, physician, and hospital characteristics, were collected from the National Health Insurance Research Database. Results: Among 162 679 patients, more were male (63.6%) than female (36.4%) and almost half (49.3%) were ≥70 years old. Most (44.9%) patients had gastrointestinal cancer. More than one-third (35.4%) of patients were prescribed strong opioids during the 12 months before death, and more than half (53.2%) of those prescribed opioids received them in the 3 months before death. Median duration of strong opioid use was 81 days before death. Patients with head/neck cancer (52.8%) or who were treated in hematology and oncology departments (45.8%) were most likely, and patients with gastrointestinal cancer (hazard ratio = 0.65; 95% confidence interval, 0.64-0.67) or treated in gastroenterology departments (hazard ratio = 0.88; 95% confidence interval, 0.84-0.93) were least likely to be prescribed strong opioids. Conclusion: Strong opioid prescriptions varied among patients with different cancer diagnoses and physicians. Information from this study can guide efforts to improve patient and physician education about cancer pain management.

AB - Aim: Pain assessment and management have been important criteria in hospital accreditation in Taiwan since 2007. We used a Taiwanese health insurance database to determine factors influencing patterns of strong opioid use in cancer patients in their final 12 months of life. Methods: Data from patients with cancer in Taiwan outpatient clinics with cancer-related deaths between 2008 and 2011 were included in the analysis. Strong opioid prescription data from the last 12 months of each patient's life, as well as patient, physician, and hospital characteristics, were collected from the National Health Insurance Research Database. Results: Among 162 679 patients, more were male (63.6%) than female (36.4%) and almost half (49.3%) were ≥70 years old. Most (44.9%) patients had gastrointestinal cancer. More than one-third (35.4%) of patients were prescribed strong opioids during the 12 months before death, and more than half (53.2%) of those prescribed opioids received them in the 3 months before death. Median duration of strong opioid use was 81 days before death. Patients with head/neck cancer (52.8%) or who were treated in hematology and oncology departments (45.8%) were most likely, and patients with gastrointestinal cancer (hazard ratio = 0.65; 95% confidence interval, 0.64-0.67) or treated in gastroenterology departments (hazard ratio = 0.88; 95% confidence interval, 0.84-0.93) were least likely to be prescribed strong opioids. Conclusion: Strong opioid prescriptions varied among patients with different cancer diagnoses and physicians. Information from this study can guide efforts to improve patient and physician education about cancer pain management.

KW - Cancer

KW - Opioid

KW - Pain

KW - Prescriptions

KW - Taiwan

UR - http://www.scopus.com/inward/record.url?scp=85042620180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042620180&partnerID=8YFLogxK

U2 - 10.1111/ajco.12865

DO - 10.1111/ajco.12865

M3 - Article

AN - SCOPUS:85042620180

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

ER -